NattoPharma ASA said its normalized net income for the third quarter was a loss of 34 Norwegian øre per share, compared with the S&P Capital IQ consensus estimate of a loss of 25 øre per share.

The per-share loss increased 14.6% year over year from 30 øre.

Normalized net income, which excludes unusual gains or losses on a pre- and after-tax basis, was a loss of 6.0 million kroner, compared with a loss of 5.2 million kroner in the prior-year period.

The normalized profit margin increased to negative 55.2% from negative 84.7% in the year-earlier period.

Total revenue grew 76.0% year over year to 10.8 million kroner from 6.2 million kroner, and total operating expenses increased 7.3% on an annual basis to 18.6 million kroner from 17.3 million kroner.

Reported net income came to a loss of 9.4 million kroner, or a loss of 54 øre per share, compared to a loss of 8.2 million kroner, or a loss of 47 øre per share, in the prior-year period.

As of Nov. 16, US$1 was equivalent to 8.51 Norwegian kroner.